Intermittent versus continuous phototherapy for the treatment of neonatal non-hemolytic moderate hyperbilirubinemia in infants more than 37 weeks of gestational age: a randomized controlled trial

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT2015112225184N1

Enrollment

Registered

2017-03-17

Start date

2016-12-21

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Icter. P55-59

Interventions

Intervention 1: Continuous phototherapy for control group. Intervention 2: Intermittent phototherapy for intervention group.

Treatment - Other

Continuous phototherapy for control group

Intermittent phototherapy for intervention group

Eligibility

Sex/Gender

All

Age

3 Days to 30 Days

Inclusion criteria

Inclusion criteria: This study has been performed on 60 neonates with indirect hyperbilirubinemia; iInclusion criteria are gestational age above 37 weeks and absence of other concomittant diseases such as hemolysis and upper limit of their bilirubin are 18 mg/dl.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Bilirubin. Timepoint: pretreatment and 6 hours after phototherapy. Method of measurement: blood sampling.;Melatonin. Timepoint: after depletion of bilirubin. Method of measurement: special kit and blood sampling.	—

Secondary

Measure	Time frame
Kernicterus. Timepoint: during of treatment. Method of measurement: sign and symptoms.;Complications. Timepoint: at the end of treatment. Method of measurement: observation.;Duration of phototherapy. Timepoint: at the end of treatment. Method of measurement: observation.;Hospital lenght of stay. Timepoint: at the end of treatment. Method of measurement: observation.;Melatonin. Timepoint: at the end of treatment. Method of measurement: blood sampling.	—

Measure

Time frame

Kernicterus. Timepoint: during of treatment. Method of measurement: sign and symptoms.;Complications. Timepoint: at the end of treatment. Method of measurement: observation.;Duration of phototherapy. Timepoint: at the end of treatment. Method of measurement: observation.;Hospital lenght of stay. Timepoint: at the end of treatment. Method of measurement: observation.;Melatonin. Timepoint: at the end of treatment. Method of measurement: blood sampling.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactRoya Taheri Tafti

Shahid Beheshty University of Medical Sciences

royataheritafti@sbmu.ac.ir; royataheritafti@yahoo.com+98 218288037

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026